-
-
-
-
-
-
-
Junshi Biosciences Announces 2022 Interim Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
Junshi Biosciences and Coherus Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
-
-
-
-
-
-
-
Junshi Biosciences and Coherus Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody
-
-
-
-
15,739 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

